This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Axcelis Technologies (ACLS) Surpasses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Axcelis (ACLS) delivered earnings and revenue surprises of 4.20% and 0.57%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Axcelis Gearing Up for Q3 Earnings: Here's What Investors Should Know
by Zacks Equity Research
ACLS' third-quarter performance is likely to have benefited from solid demand for ion implantation systems, especially in the silicon carbide space.
Axcelis Technologies (ACLS) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the most recent trading session, Axcelis Technologies (ACLS) closed at $86.09, indicating a +0.91% shift from the previous trading day.
Zacks Industry Outlook Highlights Entegris, MKS Instruments and Axcelis Technologies
by Zacks Equity Research
Entegris, MKS Instruments and Axcelis Technologies are part of the Zacks Industry Outlook article.
3 Electronics Stocks to Watch From a Prospering Industry
by Aniruddha Ganguly
The Zacks Electronics - Manufacturing Machinery industry participants, such as Entegris (ENTG), MKS Instruments (MKSI) and Axcelis Technologies (ACLS), are benefiting from increased capital spending on high-performance computing, advanced packaging and memory.
New Strong Sell Stocks for September 25th
by Zacks Equity Research
ASO, AVD and ACLS have been added to the Zacks Rank #24 (Strong Sell) List on September 25, 2024.
Axcelis Technologies (ACLS) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Axcelis Technologies (ACLS) closed the most recent trading day at $99.59, moving -1.91% from the previous trading session.
Axcelis Stock Plunges 16% YTD: Should You Buy, Hold or Sell?
by Vaishali Doshi
ACLS' performance is bearing the brunt of softness in the memory market. It notes that demand may moderate in the General Mature in the second half of 2024.
New Strong Sell Stocks for August 29th
by Zacks Equity Research
BLMN, ACLS and AIQUY have been added to the Zacks Rank #5 (Strong Sell) List on August 29, 2024.
Implied Volatility Surging for Axcelis (ACLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axcelis (ACLS) stock based on the movements in the options market lately.
New Strong Sell Stocks for August 13th
by Zacks Equity Research
ADM, ACLS and CVS have been added to the Zacks Rank #5 (Strong Sell) List on August 13, 2024.
Axcelis' (ACLS) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Axcelis (ACLS) performance gains from demand for ion implantation systems particularly in the silicon carbide space
Axcelis Technologies (ACLS) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Axcelis (ACLS) delivered earnings and revenue surprises of 11.51% and 1.63%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Factors to Note Ahead of Axcelis' (ACLS) Q2 Earnings Release
by Zacks Equity Research
Axcelis' (ACLS) second-quarter performance is likely to have benefited from increasing demand for the Purion suite of products.
Axcelis Technologies (ACLS) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Axcelis (ACLS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Does Axcelis (ACLS) Have the Potential to Rally 28.41% as Wall Street Analysts Expect?
by Zacks Equity Research
The average of price targets set by Wall Street analysts indicates a potential upside of 28.4% in Axcelis (ACLS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Roper (ROP) Gears Up to Post Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Roper's (ROP) second-quarter earnings are expected to benefit from the robust performance of the Application Software, Network Software and Tech-enabled Products segments.
How to Boost Your Portfolio with Top Computer and Technology Stocks Set to Beat Earnings
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
How to Find Strong Computer and Technology Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Implied Volatility Surging for Axcelis Technologies (ACLS) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Axcelis Technologies (ACLS) stock based on the movements in the options market lately.
Will Axcelis (ACLS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Axcelis (ACLS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Axcelis Technologies (ACLS) Just Flashed Golden Cross Signal: Do You Buy?
by Zacks Equity Research
Good things could be on the horizon when a stock experiences a golden cross event. How should investors react?
Axcelis (ACLS) Sets Up Service Offices for Customers in Japan
by Zacks Equity Research
Axcelis (ACLS) has noted that its service centers are located near the clients, which will facilitate localized support resources for its Purion ion implant equipment which is in production.
Here's Why Axcelis Technologies (ACLS) Fell More Than Broader Market
by Zacks Equity Research
Axcelis Technologies (ACLS) closed the most recent trading day at $138.73, moving -1.72% from the previous trading session.
Axcelis Technologies, Inc. (ACLS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Zacks.com users have recently been watching Axcelis (ACLS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.